Literature DB >> 12092637

Screening for prostate cancer.

S R Gambert1.   

Abstract

Carcinoma of the prostate gland is the second most common cancer among men with an age-adjusted incidence of 635 cases per 100,000 men aged 65 and older. While there are several proven methods for detecting prostate cancer, debate continues as to the best way to detect it early as well as who should receive particular screening. There are differing opinions as to proven benefit even when cancer is detected. Fortunately, newer methods continue to be developed that will hopefully reduce false positive detection rates while insuring an adequate level of screening protection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12092637     DOI: 10.1023/a:1015290429403

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  19 in total

1.  Screening for prostate cancer: what do general practitioners think?

Authors:  J Morris; B McNoe
Journal:  N Z Med J       Date:  1997-05-23

2.  The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population.

Authors:  C H Bangma; J B Rietbergen; R Kranse; B G Blijenberg; K Petterson; F H Schröder
Journal:  J Urol       Date:  1997-06       Impact factor: 7.450

3.  Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.

Authors:  W J Catalona; D S Smith; D K Ornstein
Journal:  JAMA       Date:  1997-05-14       Impact factor: 56.272

4.  An analysis of digital rectal examination and serum-prostate-specific antigen in the early detection of prostate cancer in general practice.

Authors:  T D Brett
Journal:  Fam Pract       Date:  1998-12       Impact factor: 2.267

5.  Efficiency of prostate-specific antigen and digital rectal examination in screening, using 4.0 ng/ml and age-specific reference range as a cutoff for abnormal values.

Authors:  E D Crawford; S Leewansangtong; S Goktas; K Holthaus; M Baier
Journal:  Prostate       Date:  1999-03-01       Impact factor: 4.104

6.  The effect of prostate volume, age, total prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer.

Authors:  D K Ornstein; D S Smith; P A Humphrey; W J Catalona
Journal:  J Urol       Date:  1998-04       Impact factor: 7.450

7.  Improvement of specificity in PSA-based screening by using PSA-transition zone density and percent free PSA in addition to total PSA levels.

Authors:  W Horninger; A Reissigl; H Klocker; H Rogatsch; K Fink; H Strasser; G Bartsch
Journal:  Prostate       Date:  1998-11-01       Impact factor: 4.104

8.  Relationship of prostate-specific antigen levels to prostate volume and age in mass screening subjects.

Authors:  S Akimoto; T Ichikawa; H Ito
Journal:  Urol Int       Date:  1998-08       Impact factor: 2.089

9.  Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial.

Authors:  F Labrie; B Candas; A Dupont; L Cusan; J L Gomez; R E Suburu; P Diamond; J Lévesque; A Belanger
Journal:  Prostate       Date:  1999-02-01       Impact factor: 4.104

10.  Prostate-specific antigen (PSA), PSA density and age-adjusted PSA reference values in screening for prostate cancer--a study of a randomly selected population of 2,400 men.

Authors:  O Gustafsson; E Mansour; U Norming; A Carlsson; M Törnblom; C R Nyman
Journal:  Scand J Urol Nephrol       Date:  1998-12
View more
  2 in total

1.  Does greater patient involvement in healthcare decision-making affect malpractice complaints? A large case vignette survey.

Authors:  Søren Birkeland; Marie Bismark; Michael J Barry; Sören Möller
Journal:  PLoS One       Date:  2021-07-02       Impact factor: 3.240

Review 2.  Augmenting prostate magnetic resonance imaging reporting to incorporate diagnostic recommendations based upon clinical risk calculators.

Authors:  Karisma Gupta; Jordan D Perchik; Andrew M Fang; Kristin K Porter; Soroush Rais-Bahrami
Journal:  World J Radiol       Date:  2022-08-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.